Vaccine for protection against etec-induced diarrhea comprising dmlt
AssigneeScandinavian Biopharma Holding AB, C/O Etvax AB
InventorsAnn-Mari SVENNERHOLM, Joshua TOBIAS, Nils CARLIN, Jan HOLMGREN
Life of this patent
Estimating the term…
Abstract
An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.
Claims21
(canceled)
A method of eliciting an immune response in a subject comprising orally administering a unit dose of a vaccine to the subject on at least two separate occasions separated in time by at least 3 days, wherein the vaccine comprises:
- inactivated Escherichia coli (E. coli) cells expressing enterotoxigenic E. coli (ETEC) colonization factor antigens comprising:
- inactivated E. coli expressing colonization factor A/I (CFA/I);
- inactivated E. coli expressing Coli surface antigen 3 (CS3);
- inactivated E. coli expressing Coli surface antigen 5 (CS5);
- inactivated E. coli expressing Coli surface antigen 6 (CS6);
- a hybrid protein comprising a B-subunit of E. coli heat-labile enterotoxin (LTB) and a B-subunit of cholera toxin (CTB) (LCTBA-protein);
- and
- a double mutant heat-labile toxin (dmLT) protein at 8-30 μg per unit dose, and
- wherein the vaccine comprises less than 1013 cells per unit dose and said vaccine is formulated for oral administration.
A method of immunizing a subject against enterotoxigenic E. coli (ETEC)-induced diarrhea, comprising orally administering a unit dose of a vaccine to the subject on at least two separate occasions separated in time by at least 3 days, wherein the vaccine comprises:
- inactivated Escherichia coli (E. coli) cells expressing enterotoxigenic E. coli (ETEC) colonization factor antigens comprising:
- inactivated E. coli expressing colonization factor A/I (CFA/I);
- inactivated E. coli expressing Coli surface antigen 3 (CS3);
- inactivated E. coli expressing Coli surface antigen 5 (CS5);
- inactivated E. coli expressing Coli surface antigen 6 (CS6);
- a hybrid protein comprising a B-subunit of E. coli heat-labile enterotoxin (LTB) and a B-subunit of cholera toxin (CTB) (LCTBA-protein);
- and
- a double mutant heat-labile toxin (dmLT) protein at 8-30 μg per unit dose, and
- wherein the vaccine comprises less than 1013 cells per unit dose and said vaccine is formulated for oral administration.
A vaccine, comprising inactivated Escherichia coli (E. coli) cells expressing:
- enterotoxigenic E. coli (ETEC) colonization factor antigens comprising:
- inactivated E. coli expressing colonization factor A/I (CFA/I);
- inactivated E. coli expressing Coli surface antigen 3 (CS3);
- inactivated E. coli expressing Coli surface antigen 5 (CS5);
- inactivated E. coli expressing Coli surface antigen 6 (CS6);
- a hybrid protein comprising a B-subunit of E. coli heat-labile enterotoxin (LTB) and a B-subunit of cholera toxin (CTB) (LCTBA-protein);
- and
- a double mutant heat-labile toxin (dmLT) protein at 8-30 μg per unit dose,
- wherein the vaccine comprises less than 1013 cells per unit dose and said vaccine is formulated for oral administration.
Dependencies are inferred from the claim text.